Rollema, Hans published the artcilePreclinical pharmacology of the α4β2 nAChR partial agonist varenicline related to effects on reward, mood and cognition, Related Products of quinoxaline, the publication is Biochemical Pharmacology (2009), 78(7), 813-824, database is CAplus and MEDLINE.
The pharmacol. properties and pharmacokinetic profile of the α4β2 nicotinic acetylcholine receptor (nAChR) partial agonist varenicline provide an advantageous combination of free brain levels and functional potencies at the target receptor that for a large part explain its efficacy as a smoking cessation aid. Since α4β2 and other nAChR subtypes play important roles in mediating central processes that control reward, mood, cognition and attention, there is interest in examining the effects of selective nAChR ligands such as varenicline in preclin. animal models that assess these behaviors. Here we describe results from studies on varenicline’s effects in animal models of addiction, depression, cognition and attention and discuss these in the context of recently published preclin. and preliminary clin. studies that collected data on varenicline’s effects on mood, cognition and alc. abuse disorder. Taken together, the preclin. and the limited clin. data show beneficial effects of varenicline, but further clin. studies are needed to evaluate whether the preclin. effects observed in animal models are translatable to the clinic.
Biochemical Pharmacology published new progress about 375815-87-5. 375815-87-5 belongs to quinoxaline, auxiliary class Neuronal Signaling,AChR,Natural product, name is 7,8,9,10-Tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (2R,3R)-2,3-dihydroxysuccinate, and the molecular formula is C17H19N3O6, Related Products of quinoxaline.
Referemce:
https://en.wikipedia.org/wiki/Quinoxaline,
Quinoxaline | C8H6N2 | ChemSpider